MoneyWorks4Me

Bal Pharma informs about non-applicability of large corporate

02 Apr 2024 Evaluate

Pursuant to SEBI Operational Circular No. SEBI/HO/DDHS/P/CIR/2021/613 dated August 10, 2021, read with SEBI Circular No. SEBI/HO/DDHS/DDHSRACPODI/P/CIR/2023/049 dated March 31, 2023, Bal Pharma has confirmed that the company is not a Large Corporate as per the applicability criteria mentioned in Chapter XII - Clause 1.2 of the said Operational Circular for the financial year 2023-24. The details required as per Annexure A of the said circular are enclosed.

The above information is a part of company’s filings submitted to BSE.

Bal Pharma Share Price

92.50 3.95 (4.46%)
07-Sep-2026 15:36 View Price Chart
Peers
Company Name CMP
Sun Pharma. Inds. 1899.80
Dr. Reddys Labs. 1145.00
Cipla 1395.95
Lupin 2105.00
Zydus Lifesciences 1155.00
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through: